 Lawrenceville, NJ, Jan. 26, 2021 GLOBE NEWSWIRE -- Celsion Corporation NASDAQ: CLSN, an oncology drug development company, today announced the closing of its previously announced registered direct offering of 25,925,925 shares of common stock at a purchase price of 1.35 per share, priced at-the-market under Nasdaq rules, resulting in net proceeds of 32.6 million, after deducting placement agents fees but before expenses payable by the Company. 